Nuclear factor-κB: A friend or a foe in cancer?

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1071-1080

  Shishodia, Shishir ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

activator protein 1; AP 1; EGF; epidermal growth factor; I B; I B kinase; IkappaB; IKK; IL; interleukin; MCP; NF B; nuclear factor kappa B; phorbol myristate acetate; PMA; TNF; tumor necrosis factor; vascular endothelial growth factor; VEGF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CONFERENCE PAPER; HEMATOPOIESIS; HUMAN; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; CELL DIVISION; GENE EXPRESSION REGULATION; IMMUNITY; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; NEOPLASMS; NF-KAPPA B;

EID: 4143134494     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.04.026     Document Type: Conference Paper

References (110)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 3(9):2003;745-756
2. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 47(6):1986;921-928
3. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18(49):1999;6853-6866
4. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104(4):2001;487-501
5. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13(2):2002;135-141
6. Nakai M., Qin Z.H., Chen J.F., Wang Y., Chase T.N. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. J Neurochem. 74(2):2000;647-658
7. Bellas R.E., Sonenshein G.E. Nuclear factor kappaB cooperates with c-Myc in promoting murine hepatocyte survival in a manner independent of p53 tumor suppressor function. Cell Growth Differ. 10(5):1999;287-294
8. Gagliardi M., Maynard S., Miyake T., Rodrigues N., Tjew S.L., Cabannes E., et al. Opposing roles of C/EBPbeta and AP-1 in the control of fibroblast proliferation and growth arrest-specific gene expression. J Biol Chem. 278(44):2003;43846-43854
9. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 357(9255):2001;539-545
10. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 16(6):2002;1053-1068
11. Bharti A.C., Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 64(5-6):2002;883-888
12. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274(5288):1996;782-784
13. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274(5288):1996;784-787
14. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 5(4):1999;412-417
15. Gilmore T.D. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene. 18(49):1999;6842-6844
16. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16:1998;225-260
17. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. 17(4):2002;525-535
18. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 107(6):2001;763-775
19. Feinman R., Koury J., Thames M., Barlogie B., Epstein J., Siegel D.S. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood. 93(9):1999;3044-3052
20. Griffin J.D. Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 98(8):2001;2291
21. Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 14(3):2000;399-402
22. Baron F., Turhan A.G., Giron-Michel J., Azzarone B., Bentires-Alj M., Bours V., et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood. 99(6):2002;2107-2113
23. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., Price B.D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 18(51):1999;7389-7394
24. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J. Jr., Sledge G.W. Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 17(7):1997;3629-3639
25. Wood K.M., Roff M., Hay R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene. 16(16):1998;2131-2139
26. Miyamoto S., Chiao P.J., Verma I.M. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol Cell Biol. 14(5):1994;3276-3282
27. O'Connell M.A., Cleere R., Long A., O'Neill L.A., Kelleher D. Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. J Biol Chem. 270(13):1995;7399-7404
28. Banerjee S., Bueso-Ramos C., Aggarwal B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62(17):2002;4945-4954
29. Anto R.J., Mukhopadhyay A., Shishodia S., Gairola C.G., Aggarwal B.B. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis. 23(9):2002;1511-1518
30. Shishodia S., Majumdar S., Banerjee S., Aggarwal B.B. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 63(15):2003;4375-4383
31. Chen X., Shen B., Xia L., Khaletzkiy A., Chu D., Wong J.Y., et al. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res. 62(4):2002;1213-1221
32. Gilmore T.D., Starczynowski D.T., Kalaitzidis D. RELevant gene amplification in B-cell lymphomas? Blood. 103(8):2004;3243-3244. [author reply 3244-5]
33. Gilmore T.D. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 18(49):1999;6925-6937
34. Houldsworth J., Mathew S., Rao P.H., Dyomina K., Louie D.C., Parsa N., et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 87(1):1996;25-29
35. Lu D., Thompson J.D., Gorski G.K., Rice N.R., Mayer M.G., Yunis J.J. Alterations at the rel locus in human lymphoma. Oncogene. 6(7):1991;1235-1241
36. Mayo M.W., Norris J.L., Baldwin A.S. Ras regulation of NF-kappa B and apoptosis. Meth Enzymol. 333:2001;73-87
37. Balmain A., Pragnell I.B. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature. 303(5912):1983;72-74
38. Kim B.Y., Gaynor R.B., Song K., Dritschilo A., Jung M. Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene. 21(29):2002;4490-4497
39. Kim D.W., Gazourian L., Quadri S.A., Romieu-Mourez R., Sherr D.H., Sonenshein G.E. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 19(48):2000;5498-5506
40. Fox C.J., Hammerman P.S., Cinalli R.M., Master S.R., Chodosh L.A., Thompson C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17(15):2003;1841-1854
41. Dadke D., Fryer B.H., Golemis E.A., Field J. Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res. 63(24):2003;8837-8847
42. Thornburg N.J., Pathmanathan R., Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63(23):2003;8293-8301
43. Mori N., Sato H., Hayashibara T., Senba M., Hayashi T., Yamada Y., et al. Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 99(4):2002;1341-1349
44. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332(6159):1988;83-85
45. Osborn L., Kunkel S., Nabel G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA. 86(7):1989;2336-2340
46. Biswas D.K., Cruz A.P., Gansberger E., Pardee A.B. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. 97(15):2000;8542-8547
47. Bhat-Nakshatri P., Sweeney C.J., Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 21(13):2002;2066-2078
48. Myers R.B., Brown D., Oelschlager D.K., Waterbor J.W., Marshall M.E., Srivastava S., et al. Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer. 69(5):1996;398-402
49. Farina A.R., Tacconelli A., Vacca A., Maroder M., Gulino A., Mackay A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ. 10(5):1999;353-367
50. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435(1):1998;29-34
51. Novak U., Cocks B.G., Hamilton J.A. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucl Acids Res. 19(12):1991;3389-3393
52. Wang W., Abbruzzese J.L., Evans D.B., Chiao P.J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 18(32):1999;4554-4563
53. Sliva D., English D., Lyons D., Lloyd F.P. Jr. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun. 290(1):2002;552-557
54. Mahabeleshwar G.H., Kundu G.C. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem. 278(8):2003;6209-6221
55. Loch T., Michalski B., Mazurek U., Graniczka M. [Vascular endothelial growth factor (VEGF) and its role in neoplastic processes]. Postepy Hig Med Dosw. 55(2):2001;257-274
56. Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 272(40):1997;25176-25183
57. Levine L., Lucci J.A. 3rd, Pazdrak B., Cheng J.Z., Guo Y.S., Townsend C.M. Jr., et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 63(13):2003;3495-3502
58. Yu H.G., Yu L.L., Yang Y., Luo H.S., Yu J.P., Meier J.J., et al. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology. 65(1):2003;37-45
59. Huang S., DeGuzman A., Bucana C.D., Fidler I.J. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 6(6):2000;2573-2581
60. van de Stolpe A., Caldenhoven E., Stade B.G., Koenderman L., Raaijmakers J.A., Johnson J.P., et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem. 269(8):1994;6185-6192
61. Thomsen L.L., Miles D.W. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastas Rev. 17(1):1998;107-118
62. Helbig G., Christopherson K.W. 2nd, Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 278(24):2003;21631-21638
63. Fujioka S., Sclabas G.M., Schmidt C., Frederick W.A., Dong Q.G., Abbruzzese J.L., et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 9(1):2003;346-354
64. Beg A.A., Sha W.C., Bronson R.T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 376(6536):1995;167-170
65. Doi T.S., Takahashi T., Taguchi O., Azuma T., Obata Y. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med. 185(5):1997;953-961
66. Gerondakis S., Strasser A., Metcalf D., Grigoriadis G., Scheerlinck J.Y., Grumont R.J. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA. 93(8):1996;3405-3409
67. Beg A.A., Sha W.C., Bronson R.T., Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev. 9(22):1995;2736-2746
68. Klement J.F., Rice N.R., Car B.D., Abbondanzo S.J., Powers G.D., Bhatt P.H., et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol. 16(5):1996;2341-2349
69. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 189(11):1999;1839-1845
70. Tanaka M., Fuentes M.E., Yamaguchi K., Durnin M.H., Dalrymple S.A., Hardy K.L., et al. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity. 10(4):1999;421-429
71. Liou H.C., Jin Z., Tumang J., Andjelic S., Smith K.A., Liou M.L. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol. 11(3):1999;361-371
72. Sanjabi S., Hoffmann A., Liou H.C., Baltimore D., Smale S.T. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA. 97(23):2000;12705-12710
73. Weinmann A.S., Mitchell D.M., Sanjabi S., Bradley M.N., Hoffmann A., Liou H.C., et al. Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event. Nat Immunol. 2(1):2001;51-57
74. Sha W.C., Liou H.C., Tuomanen E.I., Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 80(2):1995;321-330
75. Jefferies C., Bowie A., Brady G., Cooke E.L., Li X., O'Neill L.A. Transactivation by the p65 subunit of NF-kappaB in response to interleukin-1 (IL-1) involves MyD88, IL-1 receptor-associated kinase 1, TRAF-6, and Rac1. Mol Cell Biol. 21(14):2001;4544-4552
76. Grumont R.J., Rourke I.J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 13(4):1999;400-411
77. Snapper C.M., Zelazowski P., Rosas F.R., Kehry M.R., Tian M., Baltimore D., et al. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol. 156(1):1996;183-191
78. Kontgen F., Grumont R.J., Strasser A., Metcalf D., Li R., Tarlinton D., et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9(16):1995;1965-1977
79. Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem. 274(27):1999;19403-19410
80. Gilmore T.D., Cormier C., Jean-Jacques J., Gapuzan M.E. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene. 20(48):2001;7098-7103
81. Caamano J.H., Rizzo C.A., Durham S.K., Barton D.S., Raventos-Suarez C., Snapper C.M., et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 187(2):1998;185-196
82. Gerondakis S., Grossmann M., Nakamura Y., Pohl T., Grumont R. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. Oncogene. 18(49):1999;6888-6895
83. Weih F., Durham S.K., Barton D.S., Sha W.C., Baltimore D., Bravo R. p50-NF-kappaB complexes partially compensate for the absence of RelB: severely increased pathology in p50(-/-)relB(-/-) double-knockout mice. J Exp Med. 185(7):1997;1359-1370
84. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 3(11):1997;1285-1289
85. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11(24):1997;3482-3496
86. Grossmann M., Metcalf D., Merryfull J., Beg A., Baltimore D., Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA. 96(21):1999;11848- 11853
87. Ouaaz F., Arron J., Zheng Y., Choi Y., Beg A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity. 16(2):2002;257-270
88. Shishodia S., Aggarwal B.B. Nuclear factor-kappa B activation: a question of life and death? J. Biochem. Mol. Biol. 35(1):2002;28-40
89. Kitajima I., Soejima Y., Takasaki I., Beppu H., Tokioka T., Maruyama I. Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. Bone. 19(3):1996;263-270
90. Hu X., Tang M., Fisher A.B., Olashaw N., Zuckerman K.S. TNF-alpha-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation. J Immunol. 163(6):1999;3106-3115
91. Dudley E., Hornung F., Zheng L., Scherer D., Ballard D., Lenardo M. NF-kappaB regulates Fas/APO-1/CD95- and TCR-mediated apoptosis of T lymphocytes. Eur J Immunol. 29(3):1999;878-886
92. Ivanov V.N., Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene. 19(26):2000;3003-3012
93. Aoki M., Nata T., Morishita R., Matsushita H., Nakagami H., Yamamoto K., et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 38(1):2001;48-55
94. Dumont A., Hehner S.P., Hofmann T.G., Ueffing M., Droge W., Schmitz M.L. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappaB. Oncogene. 18(3):1999;747-757
95. Li Y., Zhang W., Mantell L.L., Kazzaz J.A., Fein A.M., Horowitz S. Nuclear factor-kappaB is activated by hyperoxia but does not protect from cell death. J Biol Chem. 272(33):1997;20646-20649
96. Grey S.T., Arvelo M.B., Hasenkamp W., Bach F.H., Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J Exp Med. 190(8):1999;1135-1146
97. Bessho R., Matsubara K., Kubota M., Kuwakado K., Hirota H., Wakazono Y., et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharmacol. 48(10):1994;1883-1889
98. Stark L.A., Din F.V., Zwacka R.M., Dunlop M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. Faseb J. 15(7):2001;1273-1275
99. Segev D.L., Ha T.U., Tran T.T., Kenneally M., Harkin P., Jung M., et al. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem. 275(37):2000;28371-28379
100. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B. Evidence that activation of nuclear factor-kappa B is essential for doxorubicin-induced cell death in myeloid and lymphoid cells. Bochem. Pharmacol. 67(2):2004;353-364
101. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem. 276(52):2001;48921-48929
102. 2-terminal protein kinase activation by tumor necrosis. Apoptosis. 4(4):1999;291-301
103. Lin K.I., DiDonato J.A., Hoffmann A., Hardwick J.M., Ratan R.R. Suppression of steady-state, but not stimulus-induced NF-kappaB activity inhibits alphavirus-induced apoptosis. J Cell Biol. 141(7):1998;1479-1487
104. Hettmann T., DiDonato J., Karin M., Leiden J.M. An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis. J Exp Med. 189(1):1999;145-158
105. van Hogerlinden M., Rozell B.L., Ahrlund-Richter L., Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res. 59(14):1999;3299-3303
106. Seitz C.S., Lin Q., Deng H., Khavari P.A. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA. 95(5):1998;2307-2312
107. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 421(6923):2003;639-643
108. Memet S., Laouini D., Epinat J.C., Whiteside S.T., Goudeau B., Philpott D., et al. IkappaBepsilon-deficient mice: reduction of one T cell precursor subspecies and enhanced Ig isotype switching and cytokine synthesis. J Immunol. 163(11):1999;5994-6005
109. Rudolph D., Yeh W.C., Wakeham A., Rudolph B., Nallainathan D., Potter J., et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 14(7):2000;854-862
110. Smahi A., Courtois G., Vabres P., Yamaoka S., Heuertz S., Munnich A., et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 405(6785):2000;466-472